This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Oncogenomics: André Bergman, Ph.D


André Bergman, Ph.D.Group Leader

About André Bergman

Research interest

Andre Bergman divides his time between treating cancer patients at the Antoni van Leeuwenhoek hospital, and working in the laboratory at the adjacent NKI, where he researches the mechanisms underlying prostate cancer development. Prostate cancer is the most prevalent malignant disease in men. It develops through distinct stages, and there is emerging evidence that the tumor microenvironment plays an important role in driving progression through the different stages. The Bergman group investigates the contribution of the microenvironment in prostate cancer development using both cancer models in the laboratory, as well as human prostate cancer. Their goal is to identify new mechanisms and targets that could be used to develop more effective therapeutic approaches.



Jeroen Kneppers

Ph.D. student


As a 2016 MSc Molecular Life Sciences graduate from Wageningen University (WUR), I have investigated gene editing tools such as CRISPR-Cas12a in the Zhang lab at the Broad Institute, Cambridge, USA. My current technical expertise are in Molecular Biology, Next Generation Sequencing (NGS) and CRISPR. My research project at the NKI focuses on interactions of nuclear receptors in the prostate cancer microenvironment. Eventually, it is my hope that our findings results in the discovery of better prognostic biomarkers, which will enable improved personalized treatment of patients.

Close this window
Linder, Simon

Simon Linder

Ph.D. student


I obtained my Bachelor's as well as my Master's degree in Biomolecular Engineering from the Technical University of Darmstadt, Germany. Within my Master's studies I have performed an internship at the Netherlands Cancer Institute in the lab of René Medema. In June 2017, I joined the groups of Wilbert Zwart and André Bergman as a Ph.D. student. Here, my project focuses on genome-wide profiling of Androgen Receptor action in clinical specimens, in search of biomarkers for prognostication and treatment selection in prostate cancer.

Close this window
Zaalberg, Anniek

Anniek Zaalberg

Ph.D. student


I received my Master's degree in Oncology from the VUmc School of Medical Sciences, during which I performed two internships. One in the group of Heinz Jacobs at the NKI and one in the group of Shawn Demehri at Massachusetts General Hospital in Boston, where I investigated the mechanism of cancer development in the context of chronic inflammatory conditions.

In September 2017 I started as a PhD student in the group of Andre Bergman and Wilbert Zwart. My research project is mainly focused on defining the immune landscape in prostate cancer, the interaction of immune- and tumor cells and the effect of androgen signaling in immune cells.

Close this window
Zhu, Yanyun

Yanyun Zhu

Ph.D. student


I did my master in Wageningen University in food safety from 2013 to 2015. During my study, I followed my interest in oncology and did both of my master thesis and internship in this field, which studied the mutation of TP53 gene and the ERα positive breast cancer, in the toxicology department (the group of professor Ivonne Rietjens) of Wageningen University. 
Motivated by my strong interest in oncology, I decided to do a Ph.D. after I finished my master. In July 2016, I joined the groups of Wilbert Zwart and Andre Bergman as a Ph.D. student. My project focusses on biomarker discovery for response to Enzalutamide treatment in prostate cancer.

Close this window

Research updates View All Updates

  • We are currently investigating the role of the adaptive immune system in initiation and development of prostate cancer in models of cancer and in human prostate cancer material.

Key publications View All Publications


Recent publications View All Publications



  • Office manager

    Astrid Jonk

  • E-mail


  • Telephone Number

    +31 (0)20 512 2569



'Research for the benefit of cancer patients'

Support us
Share this page